
CV2CoV shows improved immune protection in preclinical study
CureVac and GSK have published preclinical data investigating immune responses as well as the protective efficacy of CureVac’s first-generation vaccine candidate, CVnCoV, and second-generation vaccine candidate, CV2CoV, against SARS-CoV-2 challenge in non-human primates. The study, conducted in collaboration with Harvard Medical School, assessed cynomolgus macaques vaccinated… Read More














